Key facts
- It has raised $600K across 1 recorded rounds; the latest was Seed Round ($523K) in Aug 2023.
- Notable investors include Johnson & Johnson Innovation - JLABS.
- Optimvia has filed 4 Form Ds with the SEC since 2017, most recently Aug 2024 ($523K sold to 8 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Optimvia
Funding rounds
1 roundsAbout Optimvia
Developer of a biosynthetic manufacturing process designed for engineering enzymes and their cofactors. The company uses sulfated glycans to generate heparin as proof of principle, enabling healthcare professionals to treat and prevent blood clots caused by certain medical conditions.
- Sector
- Healthcare
- HQ
- Cincinnati, OH, United States
- Founded
- 2016
- Website
- optimvia.com/
- Ownership
- Privately Held (backing)
Optimvia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Optimvia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Optimvia in its N-PORT filings yet. We sweep new filings monthly.